Santambrogio R, Costa M, Barabino M, Opocher E
Bilio-Pancreatic Surgery Unit, Ospedale San Paolo, Milan, Italy.
Surg Endosc. 2008 Sep;22(9):2051-5. doi: 10.1007/s00464-008-9751-0. Epub 2008 Feb 5.
The optimal treatment for hepatocellular carcinoma (HCC) is surgical resection. However, only a small percentage of patients are operative candidates. The authors aimed to assess a novel operative combination of laparoscopic radiofrequency (LRF) with a selective intrahepatic vascular occlusion (SIHVO) to obtain an increased rate of total necrosis and a reduced rate of local HCC recurrences.
For this study, 37 patients with HCC in liver cirrhosis were submitted to LRF with SIHVO. An LRF was indicated for patients not amenable to liver resection who evidenced at least one of the following criteria: severe impairment of the coagulation tests, large tumors (but <5 cm) or multiple lesions requiring repeated punctures, superficial lesions adjacent to visceral structures, deep-sited lesions with a very difficult or impossible percutaneous approach, and short-term recurrence of HCC after percutaneous loco-regional therapies.
Laparoscopic ultrasound identified seven new malignant lesions (19%) undetected by preoperative imaging. There was no operative mortality. Of the 37 patients, 31 experienced no complications (84%). Computed tomography (CT) evaluation 1 month after treatment showed that a complete response with 100% necrosis had been achieved for all the patients (100%). During the follow-up period (mean, 11.8 +/- 8.2 months), new malignant nodules developed in 14 patients (42%), and 36% of these recurrences were located in the same treated segment of the HCC.
The combined LRF and SIHVO procedure proved to be a safe and effective technique at least in the short and mid term. In fact, it permitted the treatment of lesions not treatable using the percutaneous approach with a complete clearance, and it had a low morbidity rate.
肝细胞癌(HCC)的最佳治疗方法是手术切除。然而,只有一小部分患者适合手术。作者旨在评估一种腹腔镜射频(LRF)与选择性肝内血管闭塞(SIHVO)的新型手术组合,以提高完全坏死率并降低HCC局部复发率。
在本研究中,37例肝硬化合并HCC患者接受了LRF联合SIHVO治疗。对于不适合肝切除且符合以下至少一项标准的患者,采用LRF治疗:凝血功能严重受损、肿瘤较大(但<5 cm)或需要多次穿刺的多发病变、邻近内脏结构的浅表病变、经皮穿刺非常困难或无法进行的深部病变,以及经皮局部治疗后HCC短期复发。
腹腔镜超声发现7个术前影像学未检测到的新恶性病变(19%)。无手术死亡病例。37例患者中,31例无并发症(84%)。治疗后1个月的计算机断层扫描(CT)评估显示,所有患者均实现了100%坏死的完全缓解(100%)。在随访期(平均11.8±8.2个月),14例患者(42%)出现新的恶性结节,其中36%的复发位于HCC相同的治疗肝段。
至少在短期和中期,LRF联合SIHVO手术被证明是一种安全有效的技术。事实上,它能够治疗经皮途径无法治疗的病变并实现完全清除,且发病率较低。